Bioharvest Sciences Inc. (BHST)
What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'
BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
BioHarvest enters fragrance industry with AI edge - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week announced a new contract targeting the plant-based fragrance compound market, using its proprietary botanical synthesis platform. CEO Ilan Sobel said the contract focuses on a rare plant under threat from overharvesting and habitat loss.
BioHarvest inks fragrance compound deal in move into multi-billion-dollar scents market
BioHarvest Sciences Inc. (NASDAQ:BHST) said it has signed a contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking the company's entry into the multi-billion-dollar fragrance and scents industry. The contract, with an undisclosed commercial partner, targets the development of a compound derived from a threatened plant species facing overharvesting and habitat loss.
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Amit Dayal - H.C. Wainwright Susan Anderson - Canaccord Genuity Nicholas Sherwood - Maxim Group Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences First Quarter 2025 Corporate Update Conference Call.
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
BioHarvest Sciences Q1 revenue jumps on VINIA growth
BioHarvest Sciences Inc. (NASDAQ:BHST), a developer of plant-based biologics, reported a 47% year-over-year jump in first-quarter revenue on Wednesday, driven by strong demand for its flagship VINIA line of wellness products. Revenue for the quarter ended March 31 rose to $7.9 million, topping internal forecasts, as gross margins expanded by 227 basis points to 58.5%.
BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioHarvest CEO talks Nasdaq uplisting, profit targets - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week reported its financial results for 2024, showing a 99.00% year-over-year increase in revenue to 25.20 million US dollars. The company said fourth-quarter revenue was 7.30 million US dollars, up 62.00% compared to the prior year, and ahead of previously issued guidance.
BioHarvest shares rise after Q4 results show strong demand for VINIA products
BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 62% year-over-year increase in fourth-quarter revenue, reaching $7.3 million, as the biotechnology company saw strong demand for its VINIA product lines and expanded its contract development and manufacturing organization (CDMO) services. Full-year revenue nearly doubled to $25.2 million, with gross margins improving by 1,000 basis points to 55%.
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Anthony Vendetti - Maxim Group Amit Dayal - H.C. Wainwright Hunter Diamond - Diamond Equity Research Susan Anderson - Canaccord Operator Greetings, and welcome to the BioHarvest Sciences Fourth Quarter 2024 Corporate Update Conference Call.
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.70 per share a year ago.
